Mustafa Karaca1, Deniz Tural2, Emre Akar3, İbrahim Çil2, Savaş Bayrak4, Gulsum Ozet5, Orhan Kemal Yucel6, Erhan Hocaoglu1, Ahmet Ozet1. 1. Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. 2. Department of Medical Oncology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. 3. Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey, dr.emreakar@gmail.com. 4. Department of Surgery, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey. 5. Department of Hematology, Ankara Numune Training and Research Hospital, Ankara, Turkey. 6. Department of Hematology, Akdeniz University Faculty of Medicine, Antalya, Turkey.
Abstract
OBJECTIVE: The reactivation rate of chronic hepatitis B virus infection in cancer patients and chemotherapy regimens thought to be associated with hepatitis reactivation were investigated. PATIENTS AND METHODS: In all, 3,890 cancer patients were included in this study. Mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were obtained. RESULTS: Only 354 patients had positive hepatitis serology results (HBsAg+). Twenty-four patients (6.7%) with HBsAg positive serology had reactivation. In patients with hepatitis reactivation, the rates of usage of 5-fluorouracil (5-FU), cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine were found to be significantly higher than corresponding rates in patients with positive hepatitis serology results but without hepatitis reactivation (p < 0.05 for all). CONCLUSION: Increased reactivation rates were detected with usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine.
OBJECTIVE: The reactivation rate of chronic hepatitis B virus infection in cancerpatients and chemotherapy regimens thought to be associated with hepatitis reactivation were investigated. PATIENTS AND METHODS: In all, 3,890 cancerpatients were included in this study. Mortality rates, chemotherapy regimens, cancer types, number of positive hepatitis serology and reactivation rates were obtained. RESULTS: Only 354 patients had positive hepatitis serology results (HBsAg+). Twenty-four patients (6.7%) with HBsAg positive serology had reactivation. In patients with hepatitis reactivation, the rates of usage of 5-fluorouracil (5-FU), cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine were found to be significantly higher than corresponding rates in patients with positive hepatitis serology results but without hepatitis reactivation (p < 0.05 for all). CONCLUSION: Increased reactivation rates were detected with usage of 5-FU, cisplatin, cyclophosphamide, doxorubicin, steroid, rituximab, and vincristine.
Authors: James Crosby; Forrest Smith; Subramanya Shyam Ganti; Nagabhishek Moka; Samuel Bailey Journal: J Investig Med High Impact Case Rep Date: 2022 Jan-Dec